Gary Anthony Pestano Sells 16,748 Shares of Biodesix, Inc. (NASDAQ:BDSX) Stock

Biodesix, Inc. (NASDAQ:BDSX) insider Gary Anthony Pestano sold 16,748 shares of the stock in a transaction on Tuesday, February 11th. The shares were sold at an average price of $0.92, for a total value of $15,408.16. Following the completion of the sale, the insider now owns 156,008 shares of the company’s stock, valued at $143,527.36. The trade was a 9.69 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link.

Biodesix Stock Up 2.4 %

Shares of BDSX opened at $0.96 on Friday. The stock’s 50-day moving average price is $1.24 and its two-hundred day moving average price is $1.49. Biodesix, Inc. has a 12 month low of $0.86 and a 12 month high of $2.04. The company has a market capitalization of $140.09 million, a PE ratio of -2.47 and a beta of 1.06. The company has a current ratio of 3.40, a quick ratio of 3.40 and a debt-to-equity ratio of 1.30.

Hedge Funds Weigh In On Biodesix

Hedge funds and other institutional investors have recently made changes to their positions in the stock. AIGH Capital Management LLC increased its position in Biodesix by 8.8% during the 4th quarter. AIGH Capital Management LLC now owns 6,179,812 shares of the company’s stock valued at $9,455,000 after purchasing an additional 500,000 shares during the period. Wilmington Savings Fund Society FSB acquired a new position in shares of Biodesix in the 3rd quarter worth approximately $10,849,000. Samjo Management LLC bought a new stake in shares of Biodesix in the 4th quarter valued at $3,790,000. Perkins Capital Management Inc. increased its position in shares of Biodesix by 46.3% during the fourth quarter. Perkins Capital Management Inc. now owns 1,060,211 shares of the company’s stock worth $1,622,000 after buying an additional 335,429 shares during the period. Finally, Geode Capital Management LLC raised its stake in Biodesix by 2.8% during the fourth quarter. Geode Capital Management LLC now owns 827,199 shares of the company’s stock worth $1,266,000 after buying an additional 22,623 shares during the last quarter. 20.96% of the stock is owned by institutional investors and hedge funds.

Biodesix Company Profile

Biodesix, Inc operates as a data-driven diagnostic solutions company in the United States. The company offers blood-based lung tests, including Nodify XL2 and Nodify CDT tests, together marketed as part of Nodify Lung Nodule Risk Assessment testing strategy, to assess the risk of lung cancer and help in identifying the appropriate treatment pathway and help physicians in reclassifying risk of malignancy in patients with suspicious lung nodules.